Ocrelizumab for Psychosis by Autoimmunity — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ocrelizumab for Psychosis by Autoimmunity — Stella

Home/Schizo-Affective Type of Psychosis/

View on ClinicalTrials.gov

Recruiting

Back to Schizo-Affective Type of Psychosis trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Houston Methodist Research Institute, Houston, Texas

Key details

Phase

Early testing / Safety & dosing

Sponsor

The Methodist Hospital Research Institute

Collaborators

Genentech, Inc.

Enrollment target

~40 participants

Started

October 2019

Primary completion

June 2028

Age range

18 Years – 35 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.